Previous 10 | Next 10 |
2023-05-09 16:01:48 ET MannKind press release ( NASDAQ: MNKD ): Q1 GAAP EPS of -$0.04 beats by $0.01 . Revenue of $40.62M (+238.8% Y/Y) beats by $3.22M . For further details see: MannKind GAAP EPS of -$0.04 beats by $0.01, revenue of $40.62M beats by $3.22M
1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of Cash, Cash Equivalents and Investments at March 31, 2023 DA...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Tim...
2023-03-27 16:41:17 ET MannKind ( NASDAQ: MNKD ) on Monday said Lauren Sabella has joined the company as EVP and chief operating officer. Prior to joining the company, Sabella was at Acorda Therapeutics for 12 years, where she last served as COO. Pres...
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today th...
MannKind Corporation (MNKD) Q4 2022 Results Conference Call February 23, 2023 05:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Gregory Re...
Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q4 2022 Earnings Call Feb 23, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: MannKind (MNKD) Q4 2022 Earnings Call Transcript
MannKind press release ( NASDAQ: MNKD ): Q4 GAAP EPS of -$0.07 misses by $0.02 . Revenue of $36.06M (+188.0% Y/Y) beats by $0.55M . 4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021 $173 million of Cash and Cash Equivalents and Investments at ...
2022 Total Revenues of $100 million; +32% vs. 2021 2022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million 4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021 $173 million of Cash and Cash Equivalents and Investments at December 31, 2022 ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17%...
17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck ...